Published in final edited form as:

Arch Toxicol. 2015 February ; 89(2): 179–191. doi:10.1007/s00204-014-1433-1.

The Hedgehog pathway: role in cell differentiation, polarity and proliferation

Yanfei Jia,

Central Laboratory, Jinan Central Hospital Affiliated to Shandong, University, Jinan, China

Division of Hematology and Oncology, Department of Pediatrics, Wells Center for Pediatric Research, Indiana University Simon Cancer Center, Indiana University, Indianapolis, IN 46202, USA

Yunshan Wang, and

Central Laboratory, Jinan Central Hospital Affiliated to Shandong, University, Jinan, China

Jingwu Xie

Division of Hematology and Oncology, Department of Pediatrics, Wells Center for Pediatric Research, Indiana University Simon Cancer Center, Indiana University, Indianapolis, IN 46202, USA jinxie@iu.edu

Abstract

Hedgehog (Hh) is first described as a genetic mutation that has “spiked” phenotype in the cuticles of *Drosophila* in later 1970s. Since then, Hh signaling has been implicated in regulation of differentiation, proliferation, tissue polarity, stem cell population and carcinogenesis. The first link of Hh signaling to cancer was established through discovery of genetic mutations of Hh receptor gene PTCH1 being responsible for Gorlin syndrome in 1996. It was later shown that Hh signaling is associated with many types of cancer, including skin, leukemia, lung, brain and gastrointestinal cancers. Another important milestone for the Hh research field is the FDA approval for the clinical use of Hh inhibitor Erivedge/Vismodegib for treatment of locally advanced and metastatic basal cell carcinomas. However, recent clinical trials of Hh signaling inhibitors in pancreatic, colon and ovarian cancer all failed, indicating a real need for further understanding of Hh signaling in cancer. In this review, we will summarize recent progress in the Hh signaling mechanism and its role in human cancer.

Keywords

Hedgehog; Smoothened; PTCH1; Cancer; Signal transduction; Clinical trials; Animal model

Introduction

The general signaling mechanism for the Hh pathway is conserved from fly to mammal although more and distinct components are discovered in mammalian cells (Ingham and

Correspondence to: Jingwu Xie.

Conflict of interest None.

Placzek 2006). Hedgehog signaling molecules in mammal include three ligands (Sonic hedgehog—Shh, Indian hedgehog—Ihh and Desert hedgehog—Dhh), two receptors (PTCH1, PTCH2), a key signal transducer smoothened (SMO) and three transcription factors (Gli1, Gli2, Gli3) (see Fig. 1). When ligands are not present, SMO function is inhibited by another transmembrane protein Patched (PTCH1, PTCH2). Upon binding of an active Hh ligand, this inhibitory effect is lifted, allowing SMO to signal downstream, eventually leading to active transcription of Gli molecules through binding the specific consensus sequences located in the promoter region of the target genes (Kinzler and Vogelstein 1990; Sasaki et al. 1997).

In the last few years, there are significant progresses in our understanding of Hh signaling. This is reflected by the fact that nearly half of the publications on Hh signaling were produced in the last 5 years. The progress has been made in the following areas: (1) better understanding of Hh signal transduction, particularly on structures of smoothened and its small molecule regulators; (2) more reliable mouse models for Hh signaling associated carcinogenesis; (3) better understanding of Hh signaling activation mechanisms during cancer development and metastasis; (4) increasing number of clinical and preclinical studies on cancer treatment using Hh signaling inhibitors; (5) emerging evidence of Hh signaling activation in drug resistant cancer cells.

Signal transduction of the Hedgehog pathway

All Hh proteins are secreted molecules, functioning at short range on nearby cells or at long range to distant cells during development (Ingham and McMahon 2001; McMahon et al. 2003; Taipale and Beachy 2001). Hh protein precursors undergo post-translational modifications [auto-cleavage to release the N-terminal fragment (HhN), covalently binding to a cholesterol moiety at the C-terminal end and palmitoylation by a palmitoylacyltransferase at the N-terminus of HhN] (Buglino and Resh 2008; Lee et al. 1994; Porter et al. 1995, 1996). Recent data indicate that association of Hh with lipoprotein increases the Hh activity (Palm et al. 2013). Molecules involved in Hh protein transport and distribution include the transmembrane transporter-like protein dispatched (Disp) (Caspary et al. 2002; Kawakami et al. 2002; Ma et al. 2002), metalloproteinases (Dierker et al. 2009), the heparan sulfate proteoglycans Dally-like (Dlp) and Dally (Beckett et al. 2008; Lum et al. 2003) or their regulators (Baena-Lopez et al. 2008) as well as enzymes such as Sulfateless and Tout velu (Bellaiche et al. 1998; Koziel et al. 2004; Toyoda et al. 2000).

The mammalian Hh signaling pathway with major players is shown in the diagram of Fig. 1. Several molecules are engaged in reception of Hh ligands, with Patched (PTC, one PTC in fly and two PTCs in vertebrates—PTCH1 and PTCH2) as the major receptor (Stone et al. 1996). Studies from cultured cells indicate that PTC inhibits SMO at a substoichiometric concentration (Taipale et al. 2002). Hhinteracting protein (HIP) can compete with PTC on Hh binding, resulting in negative regulation of Hh signaling (Chuang and McMahon 1999). On the other hand, interference hedgehog (Ihog) or its vertebrate homologues cell adhesion molecule-related/down-regulated by oncogenes (CDO) and BOC (brother of CDO), GAS1 and Glypican-3 (GPC3), serve as co-receptors of Hh (Allen et al. 2007; Capurro et al. 2008; Martinelli and Fan 2007; Okada et al. 2006; Seppala et al. 2007; Tenzen et al. 2006; Yao et

al. 2006; Zhang et al. 2006). In contrast to the inhibitory effect of GPC3, Glypican-5 (GPC5) and other HSPGs are shown to stimulate Hh signaling by promoting binding of sonic Hh to PTCH1 (Li et al. 2011b; Witt et al. 2013). The effect of GPC5 and Ihog homologues requires another secreted extracellular molecule—wnt inhibitory factor-1 (WIF1) (Avanesov et al. 2012; Sanchez-Hernandez et al. 2012). It is still not entirely clear how binding of Hh proteins results in the pathway activation. It is proposed that PTC limits SMO signaling via transporting endogenous small molecules specifically targeted to SMO. Candidates of these small molecules include PI4P, lipoproteins and pro-vitamin D3 (Bijlsma et al. 2006; Callejo et al. 2008; Khaliullina et al. 2009; Yavari et al. 2010). It is currently not very clear how these molecules regulate SMO signaling. Upon binding to Hh, PTCH1 undergoes Smurf1/2-mediated monoubiquitination at multiple sites and enters endocytosis pathway, resulting in protein degradation in lysosome (Huang et al. 2013; Yue et al. 2014).

It is now known that glucocorticoid molecules can modulate SMO signaling through regulating its ciliary localization (Wang et al. 2012a). Several recent reports support SMO to G protein coupling (Molnar et al. 2007; Ogden et al. 2008; Philipp et al. 2008; Riobo et al. 2006) but the functional involvement of G protein coupling of SMO in carcinogenesis has not been convincingly demonstrated. Gα can also regulate Gli proteins independent of SMO (Douglas et al. 2011). It is quite clear that two important events occur during SMO signaling in mammalian cells. First, SMO protein undergoes conformational change to favor SMO signaling (Zhao et al. 2007) although the regulatory mechanism underlying this conformational change is not clear. Recent data suggest that SMO undergoes monoubiquitination, and the process is blocked by USP8 (Li et al. 2012a; Xia et al. 2012). Second, ciliary translocation of mammalian SMO protein is critical for Hh signaling (Corbit et al. 2005; Hoover et al. 2008; Huangfu and Anderson 2005; Huangfu et al. 2003; May et al. 2005; Zhang et al. 2005). Several reports now link neuropilin 1/2 (Nrp1/2) to SMO signaling (Cao et al. 2008; Hillman et al. 2011; Parra and Zou 2010; Snuderl et al. 2013).

Manipulation of SMO signaling is feasible because numerous small molecules can inhibit SMO signaling. Furthermore, a few small molecules can promote SMO signaling. Structural studies reveal the specific sites for SMO-small molecule interaction, with the cysteine rich N-terminal domain binding to the cyclopamine and another pocket binding to LY2940680 (Bai et al. 2014; Duarte et al. 2013; Myers et al. 2013; Nachtergaele et al. 2013; Nedelcu et al. 2013; Rana et al. 2013; Wang et al. 2013; Weierstall et al. 2014). These studies indicate that not all SMO inhibitors bind to the same site, which may explain distinct clinical outcomes from different small molecule SMO inhibitors.

Several molecules are identified to be genetically downstream of SMO in *Drosophila*, including COS2, Suppressor of Fused (SuFu) and Fused. Recent study has identified two more molecules (p66beta and Mycbp) involved in regulation of Gli molecules (Lin et al. 2014). A COS2 homologue, kinesin like-protein KIF7, functions in the Hh pathway but is not directly associated with SMO (Cheung et al. 2009; Endoh-Yamagami et al. 2009; Hsu et al. 2011; Law et al. 2012; Li et al. 2012), suggesting that KIF7 does not contain all COS2 functions in vertebrates. Mutations of KIF7 have been detected in acrocallosal syndrome (Putoux et al. 2011, 2012; Speksnijder et al. 2013; Walsh et al. 2013). Gli3 gene mutations are also discovered in this syndrome (Speksnijder et al. 2013). In contrast, the phenotype of

Fused^{-/-} mice is very different from *Shh* null mice (Chen et al. 2005; Merchant et al. 2005; Wilson et al. 2009), indicating that *Fused* is not critical for Hh signaling during early embryonic development in mice.

In addition to the *Drosophila* homologues, mammalian cells have several novel cytoplasmic regulators of Hh signaling, including Rab23 (Eggenchwil et al. 2001) and tectonic (Reiter and Skarnes 2006). Rab23 and tectonic are all negative regulators downstream of SMO. We have shown that Rab23 is involved in Gli-SuFu interaction (Li et al. 2011a) (see Fig. 1). Unlike many Rab proteins, we found that Rab23 is localized both in the nucleus and in cytoplasm (Huang et al. 2010), suggesting that Rab23 may have other unrevealed functions apart from membrane trafficking. Tectonic 1/2, on the other hand, is involved in ciliary transportation of membrane-associated proteins, such as SMO (Garcia-Gonzalo et al. 2011). Mutations of tectonic1/2 genes have been found in several genetic disorders such as Meckel and Joubert syndromes (Garcia-Gonzalo et al. 2011; Huppke et al. 2014; Shaheen et al. 2011).

The ultimate effect of Hh signaling is activation of downstream Gli transcription factors, which regulate target genes in part by direct binding a consensus-binding site (5'-tggtggtc-3') in the promoter (Kinzler et al. 1988; Kinzler and Vogelstein 1990; Parker et al. 2011; Ruppert et al. 1988; Sasaki et al. 1997). The activity of Gli transcription factors can be regulated at several levels. First, nuclear-cytoplasmic shuttling of Gli molecules is tightly regulated (Barnfield et al. 2005; Kogerman et al. 1999; Sheng et al. 2006; Stecca et al. 2007). Protein kinase A can retain Gli1 protein in the cytoplasm via a PKA site in the nuclear localization signal domain (Sheng et al. 2006) whereas activated Ras signaling induces Gli nuclear localization (Stecca et al. 2007). Second, ubiquitination, acetylation and protein degradation of Gli molecules is regulated by several distinct mechanisms, including β -TRCP-, cul3/BTB- and numb/ Itch-mediated Gli ubiquitination, sumoylation and acetylation (Canettieri et al. 2010; Coni et al. 2013; Di Marcotullio et al. 2006; Han et al. 2012; Huntzicker et al. 2006; Jiang 2006; Pan et al. 2006; Wang and Li 2006). In addition, Gli3 (Gli2 to a less extent) can be processed into transcriptional repressors, which may be mediated by the β -TRCP E3 ligase (Wang and Li 2006; Zhang et al. 2009). SuFu not only prevents nuclear translocation of Gli molecules, but also inhibits Gli1-mediated transcriptional activity (Cheng and Bishop 2002; Li et al. 2013; Wang et al. 2010a). Other mechanisms to modify Gli functions include interaction with a negative regulator sucrose non-fermenting 5 (SNF5) (Jagani et al. 2010) and a positive regulator protein kinase C isoform τ/λ (PK τ/λ) (Atwood et al. 2013). It has been shown that BET bromodomain containing proteins, such as BRD4, occupy the promoters of Gli1 and Gli2, and inhibition of BRD4 by JQ1 can suppress Gli-mediated reporter gene activity (Tang et al. 2014). In fact, a novel BRD4 specific compound has been identified to inhibit Gli transcriptional activity (Long et al. 2014).

Several feedback regulatory loops exist in this pathway to maintain a certain level of Hh signaling in a given cell. PTC, HIP, GAS1, neuropilins (npr) and Gli1 are both components as well as target genes of this pathway. PTC and HIP provide negative feedback regulation whereas Gli1 and Nrp1/2 form positive regulatory loops. On the other hand, GAS1 is down-regulated by the Hh pathway but it is a positive regulator for Hh signaling [reviewed in

(Yang et al. 2010)]. Alterations of these loops would lead to abnormal signaling of this pathway, such as inactivation of PTCH1 in BCCs.

Role of Hh signaling in differentiation, polarity and proliferation

Hedgehog was initially discovered as a segment polarity gene in *Drosophila* embryonic development. As an important morphogen, Hh forms a gradient to guide cells during embryonic development. In the developing spinal cord for example, Shh is secreted from the notochord and the floor plate, and spread to other parts of the spinal cord. It is demonstrated in vitro that Shh is a critical morphogen for motor neuron differentiation. This spatial and temporal gradient of Shh promotes the formation of different types neural subtypes, which has been nicely summarized elsewhere (Ribes and Briscoe 2009).

Hh signaling is also critical for cellular communications between the mesenchyme and the developing hair follicle. In the anagen phase of hair cycle in postnatal life, Shh is secreted by the dermal cells near the base of hair follicle to promote cell division/differentiation of bulge stem cells. Latter stages of hair cycle will be affected without Hh signaling. In catagen phase, Hh signaling is not detectable (Hsu et al. 2014).

The developing limb in vertebrates is one of the best model systems to study pattern formation and polarity. Shh is produced in the polarizing region, with Shh concentration high in the posterior region and low in the anterior region. In addition to Hh signaling, Wnt5a, FGFs and retinoic acid signaling all have gradients. The interactions of these morphogens give rise to the precise position for each digit. There are several excellent reviews on limb development (Benazet and Zeller 2009; Hui and Angers 2011; Johnson et al. 1994; Suzuki 2013).

The direct regulation of cell proliferation by Hh signaling is shown in cultured cerebella cells in the presence of recombinant Shh protein (Wallace 1999). There is a lot of in vivo evidence to show regulation of Hh signaling on cell proliferation. For example, numerous gene knockout mice show altered cell proliferation in neurons (Dahmane and Ruiz i Altaba 1999; Wechsler-Reya and Scott 1999) and hair follicles (Hsu et al. 2014). The exact molecular mechanism underlying cell proliferation regulation varies from cell type to cell type, but it is known that Hh signaling regulates gene expression of cell cycle- related molecules such as cyclin D2 and N-myc.

The link of Hh signaling to cancer

The initial link between Hh signaling and human cancer was made from genetic studies of a rare and hereditary form of BCC- Basal Cell Nevus Syndrome (also named as Gorlin syndrome by the famous dentist Robert Gorlin), which often harbor genetic mutations of human *PTCH1* (Epstein 2001; Hahn et al. 1996; Johnson et al. 1996). Gorlin syndrome has two distinct sets of phenotypes: an increased risk to developing cancers such as BCCs, medul-loblastomas, rhabdomyosarcomas and meningiomas as well as developmental defects such as bifid ribs, ectopic calcification (Gorlin 1987).

Genetic mutations of the Hh signaling molecules are more frequently found in BCCs and some (~30 %) medulloblastomas, with *PTCH1* and *SMO* frequently mutated (Couve-Privat et al. 2002; Lam et al. 1999; Reifenberger et al. 1998, 2005; Xie et al. 1998). In addition, cancers associated with Gorlin syndrome, including rhabdomyosarcoma (Pressey et al. 2011; Tostar et al. 2006) and meningiomas (Aavikko et al. 2012; Clark et al. 2013; Kijima et al. 2012), are reported to have elevated Hh target gene expression, but genetic mutations of the Hh pathway are rare. Furthermore, activated Hh signaling has been detected in a variety of human cancer types, either in the tumor or in the stroma (Yang et al. 2010; Fei et al. 2012; Rodriguez-Blanco et al. 2013; Shin et al. 2011).

Genetically engineered mice with *Ptch1* and *Smo* genes have generated more convincing evidence for the critical role of Hh signaling in cancer. In addition to BCC and medulloblastomas, rhabdomyosarcomas develop in mice with expression of oncogenic *SmoM2* or knockout of *Ptch1* (Hahn et al. 1998; Hatley et al. 2012; Ignatius et al. 2012; Nitzki et al. 2011). One surprising finding from tissue specific *Ptch1* knockout is the development of gastrointestinal stromal-like tumors (GIST) (Pelczar et al. 2013), suggestive a role of Hh signaling in GIST. In the situation of small cell lung cancer (SCLC) mouse model, expression of oncogenic *SmoM2* increases the tumor number whereas *Smo* knockout reduces the tumor number (Park et al. 2011). Recent study of Barrett's esophagus indicates that Sonic Hh expression in the epithelium of esophagus can lead to stromal expression of Hh signaling target genes, which is similar to the human situation (Wang et al. 2010b; Yang et al. 2012). In contrast, tissue specific expression of oncogenic *Smo* molecule *SmoM2* has no effects on K-Ras-induced pancreatic cancer development (Tian et al. 2009) or on prostate cancer (Mao et al. 2006). The negative data, however, do not rule out the promoting effects of Hh signaling for tumor metastasis, a major factor for cancer mortality. Currently, there are only a limited number of mouse models for cancer metastasis. Even for the available animal models for cancer metastasis, several variable factors make cancer metastasis models less robust, such as mouse genetic backgrounds, low incidence and long duration to observe metastasis in mice.

Hh signaling in tumor initiation, promotion and metastases

It is likely that Hh signaling plays distinct roles in different types of cancer [reviewed in (Yang et al. 2010)]. Based on recent publications, we identified three major roles of Hh signaling during cancer development: a tumor development driver, a tumor promoter, or a regulator for residual cancer cells after therapy (see Fig. 2 for details). For example, activated Hh signaling can drive development of BCCs, medulloblastomas, rhabdomyosarcoma, GIST and Barrett's esophagus (Aszterbaum et al. 1999; Goodrich et al. 1997; Hahn et al. 1998; Hatley et al. 2012; Pelczar et al. 2013; Wang et al. 2010b). Hh signaling in these lesions serves as a tumor driver, at least in the mouse model. As to SCLC, Hh signaling can promote cancer development but is not sufficient to drive tumor formation (Park et al. 2011). Thus, Hh signaling activation is a tumor promoter for development of SCLC. In pancreatic cancer, on the other hand, inhibition of Hh signaling does not affect tumor formation but can promote tumor metastasis (Bailey et al. 2008, 2009; Chang et al. 2013; Feldmann et al. 2007, 2008; Gu et al. 2013; Olive et al. 2009; Tang et al. 2012). For other cancer types, Hh signaling may regulate the number of cancer stem cells or the tumor

microenvironment, such as leukemia and liver cancer (Boyd et al. 2013; Zhao et al. 2009). As more in vivo data are available, we predict more revelation of the tumor promoting role of Hh signaling. Tumor recurrence after therapy is a major issue in clinical care of cancer patients, such as chemotherapy or radiotherapy resistance, and will be discussed later in the review. For some cancer types, Hh signaling may not have any roles to play at all.

Activation of Hh signaling does not work alone, cross-talks with other signaling pathways play critical roles during cancer development and metastasis. Earlier studies indicated that *Ptch1*^{+/-} mice with *P53* knockout all developed medulloblastomas whereas <30 % of *Ptch1*^{+/-} mice (with wild type *P53*) had this type of tumor (Romer et al. 2004). We have shown that skin specific knockout of *Stat3* or its upstream activator *Il1ra* significantly reduced Hh signaling-mediated BCC formation (Gu et al. 2012). Increasing data have indicated close collaboration between Hh signaling and growth factor signaling pathways. Our earlier work indicated that PDGFR α is regulated by Hh signaling and is responsible for cell proliferation in BCCs (Xie et al. 2001). Now more links are reported between Hh and other pathways, including EGF, IGF, TGF β , mTOR/ S6K1, RACK1, Notch and PKC (Eberl et al. 2012; Fan et al. 2010; Fernandez et al. 2012; Hsieh et al. 2011; Johnson et al. 2011; Keysar et al. 2013; Mainwaring and Kenney 2011; Shi et al. 2012; Wang et al. 2012b; Yang et al. 2010). While some of these molecules are involved in regulation of tumor microenvironment such as TGF β , others are known to regulate cancer stem cells, such as PDGFR α and Notch. We will have more discussion on cancer stem cells in “Hedgehog signaling, cancer stem cell and residual cancer cells” section.

Increasing evidence indicates that Hh signaling plays an important role during tumor metastasis in several types of cancer, such as pancreatic and breast cancers (Gu et al. 2013; Heller et al. 2012). Studies from many groups indicate activation of Hh signaling in the stromal as well as tumor compartments in metastatic pancreatic cancer [Abbruzzese and National Institutes of Health (US) 2007; Bailey et al. 2009; Feldmann et al. 2007, 2008; Gu et al. 2013; Olive et al. 2009; Tang et al. 2012]. In fact, Hh signaling inhibitors are effective in suppressing tumor metastases of pancreatic cancer (Gu et al. 2013). Hh signaling also regulates bone homeostasis as well as bone metastasis in breast cancer, which is independent of the Hh ligands (Johnson et al. 2011). During tumor metastasis, Hh signaling activation is observed both in the tumor compartment and in the stroma (Gu et al. 2013). The molecules mediated Hh's metastatic functions remain largely untested, but there are reports to indicate the following molecules: snail, TGF β , wnt, HGF and muc5AC (Gu et al. 2013; Inaguma et al. 2010; Javelaud et al. 2012; Joost et al. 2012; Li et al. 2007b). Further studies will be needed to understand the molecular basis by which Hh signaling mediates cancer metastases.

Hedgehog signaling, cancer stem cell and residual cancer cells

Increasing evidence indicates that Hh signaling is critical for cancer stem cell maintenance and function (Dierks et al. 2008; Read et al. 2009; Zhao et al. 2009). For example, leukemia stem cell maintenance and expansion is dependent on Hh signaling (Dierks et al. 2008; Zhao et al. 2009). The effect of Hh signaling on normal hematopoietic stem cell (HSC) population, however, is still quite controversial, with some showing some effects but others

with no effects (Gao et al. 2009; Hofmann et al. 2009; Merchant et al. 2010; Siggins et al. 2009; Zhao et al. 2009). Based on cancer stem cell theory, it is anticipated that Hh signaling activation exerts resistance to cancer chemotherapy and radiotherapy (Reya et al. 2001). Several studies indeed have shown that Hh signaling activation is associated with chemotherapy or radiotherapy resistance (Sims-Mourtada et al. 2006; Yoshikawa et al. 2008). Hh signaling inhibitor IPI-926 enhances delivery of chemotherapeutic drug gemcitabine in a mouse model of pancreatic cancer (Olive et al. 2009). However, more recent data indicate that genetic depletion of Shh actually promotes tumor development, suggesting that the role of Hh signaling in pancreatic cancer development is not simply positive or negative role (Ozdemir et al. 2014; Rhim et al. 2014; Shin et al. 2014).

Based on the published data, we propose that Hh signaling may help regulate cancer stem cells, which are generally insensitive to chemotherapy and radiotherapy. There is evidence to indicate that Hh signaling regulates expression of cancer stem cell-related markers: such as ALDH1, Bmi1, snail, Wnt2, PDGFR α , jagged-1, CD44 and c-MET (Gu et al. 2013; Joost et al. 2012; Liu et al. 2006; Song et al. 2011; Takahashi et al. 2011; Takebe et al. 2011; Tanaka et al. 2009). The level of Hh expression is often higher in the cancer stem cell population in several cancer types (Bar et al. 2007; Clement et al. 2007; Li et al. 2007a; Su et al. 2012; Visbal et al. 2011). Thus, we have reasons to believe that inhibition of Hh signaling may be effective in reducing the number of cancer stem cells, which may play an important role in chemotherapy and radiotherapy resistance.

Chemotherapy and radiotherapy play an important role in the clinical care of cancer patients, but resistance to these treatments remains a major obstacle in cancer patient care. Increasing evidence shows higher Hh signaling in chemoresistant cancer cells. Emerging evidence also indicates that Hh signaling may regulate cell's tolerance to anticancer agents. Smoothed antagonists thus have offered valuable therapeutic strategies against cancer, either alone or with chemotherapeutic agents. One Smo inhibitor, vismodegib (GDC-0449), is a FDA-approved drug for the treatment of locally advanced and metastatic BCC. Other four Smo inhibitors have progressed into phase II clinical trials (NVP-LDE225, IPI-926, XL-139, and LY2940680). In ovarian cancer, LDE225 increases paclitaxel sensitivity via regulation of MDR1 (Steg et al. 2012b). Vismodegib is sufficient to drive UDP glucuronosyltransferase (UGT1A)-dependent glucuronidation of ribavirin and Ara-C, leading to reduced drug resistance in acute myeloid leukaemia (AML) (Zahreddine et al. 2014).

Identification of the upstream regulators and downstream mediators of Hh pathway during chemotherapeutic drug response may be critical to understand how Hh signaling causes resistance to different chemotherapeutic agents. Overexpression of MAP3K10 promoted the proliferation and decreased the gemcitabine sensitivity of pancreatic cancer cells, through up-regulation of Gli1 and Gli2 (An et al. 2013). Crosstalk between PI3K/AKT signaling and the Hh pathway has been reported in a number of cancer, including prostate and breast cancers. A recent study reported an important effect of Hh signaling on docetaxel resistance in prostate cancer (Domingo-Domenech et al. 2012). Combination of Notch and Hh signaling inhibitors was able to reverse docetaxel resistance both in cultured cells and in xenografts. Activation of Hh signaling via PI3K is also reported in tamoxifen-resistance breast cancer (Ramaswamy et al. 2012), and combination of Hh signaling inhibitor

GDC-0449 with tamoxifen significantly reduced cell colony formation and tumor development in xenografts. Elevated Hh signaling increases expression of BCL2, enhances cell proliferation and protects cells against chemotherapy induced apoptosis (Das et al. 2013; Domingo-Domenech et al. 2012). These results suggest that the function of Hh signaling in drug resistance may vary based on tumor types and the type of chemotherapeutic agents. Therefore, it is necessary to consider the mechanisms of action for different drug treatments.

Activated Hh signaling is also shown to be responsible for drug resistance in ovarian cancer, cervical cancer and myeloid leukemic cells (Chaudary et al. 2012; Queiroz et al. 2010; Steg et al. 2012a). Recent study suggests that Hh signaling may be associated with anti-EGFR therapy (targeted therapy) resistance in head and neck cancer (Keysar et al. 2013). The exact mechanisms by which Hh signaling activation confers drug resistance are not entirely clear, but it is reported that Hh signaling can regulate expression of several drug resistance related genes such as ABCG2, MDR (Queiroz et al. 2010; Singh et al. 2011). The cancer stem cell theory can also explain some of the mechanisms.

Overcoming recurrence to radiotherapy is also very challenging, but recent studies suggest that inhibiting Hh signaling may help mitigate radiotherapy resistance in pancreatic and head/neck cancer. For pancreatic cancer, we found that combination of Hh signaling inhibitor BMS833932 (Yang et al. 2010) and radiation could significantly reduce the number of lymph node metastasis (Gu et al. 2013). Similarly, high expression of Gli1 is reported to be associated with lymph node metastases and tumor progression after radiotherapy in squamous cell carcinomas of head/ neck (Lin et al. 2013).

Summary and future perspectives

In summary, the link of the Hh signaling pathway to a variety of human cancer implies the high relevance of studying Hh signaling to human health. Despite of the impressive progress in Hh signaling in cancer, there are several challenges ahead of us in order to achieve better understanding of signaling mechanisms as well as to achieve clinical benefits for the cancer patients. First, because elevated transcriptional activity of Gli molecules by other signaling pathways (such as PI3K or TGF β signaling) (Javelaud et al. 2012; Ramaswamy et al. 2012) occurs frequently in several types of cancer, specific inhibitors to SMO will not be effective in many situations. Thus, discovery and synthesis of Gli specific inhibitors is in great need for effective suppression of non-canonical Hh signaling in cancer. Another area is to develop reliable, physiologically relevant and reproducible mouse models for cancer metastases, which will allow us to test and optimize drug dosages to minimize the side effects. Third, Hh signaling does not work alone, identifying the optimal combination between Hh signaling inhibitors, chemotherapeutic agents or other targeted therapeutic agents in a given tumor type will help us to reduce the medical burden of cancer metastases. It is anticipated that additional novel therapeutic strategies will be developed for cancer clinical trials using Hh signaling inhibitors in the next few years.

Acknowledgments

Current research in my laboratory is supported by grants from the National Cancer Institute CA155086, Riley Children's Foundation and Wells Center for Pediatric Research. Due to space limit, we could not include many

important findings in this review but want to take this opportunity to thank all the investigators in this field for their works.

References

- Aavikko M, Li SP, Saarinen S, et al. Loss of SUFU function in familial multiple meningioma. *Am J Hum Genet.* 2012; 91(3):520–526. [PubMed: 22958902]
- Abbruzzese, JL. National Institutes of Health (US). Are there new targets for pancreatic cancer therapeutics?. National Institutes of Health, Bethesda, MD. 2007. <http://videocast.nih.gov/launch.asp?13834>
- Allen BL, Tenzen T, McMahon AP. The Hedgehog-binding proteins Gas1 and Cdo cooperate to positively regulate Shh signaling during mouse development. *Genes Dev.* 2007; 21(10):1244–1257. [PubMed: 17504941]
- An Y, Cai B, Chen J, et al. MAP3K10 promotes the proliferation and decreases the sensitivity of pancreatic cancer cells to gemcitabine by upregulating Gli-1 and Gli-2. *Cancer Lett.* 2013; 329(2): 228–235. [PubMed: 23178452]
- Aszterbaum M, Epstein J, Oro A, et al. Ultraviolet and ionizing radiation enhance the growth of BCCs and trichoblastomas in patched heterozygous knockout mice. *Nat Med.* 1999; 5(11):1285–1291. [PubMed: 10545995]
- Atwood SX, Li M, Lee A, Tang JY, Oro AE. GLI activation by atypical protein kinase C iota/lambda regulates the growth of basal cell carcinomas. *Nature.* 2013; 494(7438):484–488. [PubMed: 23446420]
- Avanesov A, Honeyager SM, Malicki J, Blair SS. The role of glypicans in Wnt inhibitory factor-1 activity and the structural basis of Wif1's effects on Wnt and Hedgehog signaling. *PLoS Genet.* 2012; 8(2):e1002503.
- Baena-Lopez LA, Rodriguez I, Baonza A. The tumor suppressor genes dachshous and fat modulate different signalling pathways by regulating dally and dally-like. *Proc Natl Acad Sci USA.* 2008; 105(28):9645–9650. [PubMed: 18621676]
- Bai Q, Shen Y, Jin N, Liu H, Yao X. Molecular modeling study on the dynamical structural features of human smoothened receptor and binding mechanism of antagonist LY2940680 by metadynamics simulation and free energy calculation. *Biochim Biophys Acta.* 2014; 1840(7):2128–2138. [PubMed: 24637074]
- Bailey JM, Swanson BJ, Hamada T, et al. Sonic hedgehog promotes desmoplasia in pancreatic cancer. *Clin Cancer Res.* 2008; 14(19):5995–6004. [PubMed: 18829478]
- Bailey JM, Mohr AM, Hollingsworth MA. Sonic hedgehog paracrine signaling regulates metastasis and lymphangiogenesis in pancreatic cancer. *Oncogene.* 2009; 28(40):3513–3525. [PubMed: 19633682]
- Bar EE, Chaudhry A, Lin A, et al. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. *Stem Cells.* 2007; 25(10):2524–2533. [PubMed: 17628016]
- Barnfield PC, Zhang X, Thanabalasingham V, Yoshida M, Hui CC. Negative regulation of Gli1 and Gli2 activator function by Suppressor of fused through multiple mechanisms. *Differentiation.* 2005; 73(8):397–405. [PubMed: 16316410]
- Beckett K, Franch-Marro X, Vincent JP. Glypican-mediated endocytosis of hedgehog has opposite effects in flies and mice. *Trends Cell Biol.* 2008; 18(8):360–363. [PubMed: 18603427]
- Bellaiche Y, The I, Perrimon N. Tout-velu is a Drosophila homologue of the putative tumour suppressor EXT-1 and is needed for Hh diffusion. *Nature.* 1998; 394(6688):85–88. [PubMed: 9665133]
- Benazet JD, Zeller R. Vertebrate limb development: moving from classical morphogen gradients to an integrated 4-dimensional patterning system. *Cold Spring Harb Perspect Biol.* 2009; 1(4):a001339. [PubMed: 20066096]
- Bijlsma MF, Spek CA, Zivkovic D, van de Water S, Rezaee F, Pep-pelenbosch MP. Repression of smoothened by patched-dependent (pro-)vitamin D3 secretion. *PLoS Biol.* 2006; 4(8):e232. [PubMed: 16895439]

- Boyd AL, Salci KR, Shapovalova Z, McIntyre BA, Bhatia M. Nonhematopoietic cells represent a more rational target of in vivo hedgehog signaling affecting normal or acute myeloid leukemia progenitors. *Exp Hematol*. 2013
- Buglino JA, Resh MD. Hhat is a palmitoylacyltransferase with specificity for *N*-palmitoylation of sonic hedgehog. *J Biol Chem*. 2008; 283(32):22076–22088. [PubMed: 18534984]
- Callejo A, Culi J, Guerrero I. Patched, the receptor of hedgehog, is a lipoprotein receptor. *Proc Natl Acad Sci USA*. 2008; 105(3):912–917. [PubMed: 18198278]
- Canettieri G, Di Marcotullio L, Greco A, et al. Histone deacetylase and Cullin3-REN (KCTD11) ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation. *Nat Cell Biol*. 2010; 12(2):132–142. [PubMed: 20081843]
- Cao Y, Wang L, Nandy D, et al. Neuropilin-1 upholds dedifferentiation and propagation phenotypes of renal cell carcinoma cells by activating Akt and sonic hedgehog axes. *Cancer Res*. 2008; 68(21):8667–8672. [PubMed: 18974107]
- Capurro MI, Xu P, Shi W, Li F, Jia A, Filmus J. Glypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding. *Dev Cell*. 2008; 14(5):700–711. [PubMed: 18477453]
- Caspary T, Garcia-Garcia MJ, Huangfu D, et al. Mouse dispatched homolog is required for long-range, but not juxtacrine, Hh signaling. *Curr Biol*. 2002; 12(18):1628–1632. [PubMed: 12372258]
- Chang Q, Foltz WD, Chaudary N, Hill RP, Hedley DW. Tumor-stroma interaction in orthotopic primary pancreatic cancer xenografts during hedgehog pathway inhibition. *Int J Cancer*. 2013; 133(1):225–234. [PubMed: 23280784]
- Chaudary N, Pintilie M, Hedley D, et al. Hedgehog pathway signaling in cervical carcinoma and outcome after chemoradiation. *Cancer*. 2012; 118(12):3105–3115. [PubMed: 22028038]
- Chen MH, Gao N, Kawakami T, Chuang PT. Mice deficient in the fused homolog do not exhibit phenotypes indicative of perturbed hedgehog signaling during embryonic development. *Mol Cell Biol*. 2005; 25(16):7042–7053. [PubMed: 16055716]
- Cheng SY, Bishop JM. Suppressor of Fused represses Gli-mediated transcription by recruiting the SAP18-mSin3 corepressor complex. *Proc Natl Acad Sci USA*. 2002; 99(8):5442–5447. [PubMed: 11960000]
- Cheung HO, Zhang X, Ribeiro A, et al. The kinesin protein Kif7 is a critical regulator of Gli transcription factors in mammalian hedgehog signaling. *Sci Signal*. 2009; 2(76):ra29. [PubMed: 19549984]
- Chuang PT, McMahon AP. Vertebrate Hedgehog signalling modulated by induction of a Hedgehog-binding protein. *Nature*. 1999; 397(6720):617–621. [PubMed: 10050855]
- Clark VE, Erson-Omay EZ, Serin A, et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. *Science*. 2013; 339(6123):1077–1080. [PubMed: 23348505]
- Clement V, Sanchez P, de Tribolet N, Radovanovic I, Ruiz i Altaba A. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. *Curr Biol*. 2007; 17(2):165–172. [PubMed: 17196391]
- Coni S, Antonucci L, D'Amico D, et al. Gli2 acetylation at lysine 757 regulates hedgehog-dependent transcriptional output by preventing its promoter occupancy. *PLoS One*. 2013; 8(6):e65718. [PubMed: 23762415]
- Corbit KC, Aanstad P, Singla V, Norman AR, Stainier DY, Reiter JF. Vertebrate smoothened functions at the primary cilium. *Nature*. 2005; 437(7061):1018–1021. [PubMed: 16136078]
- Couve-Privat S, Bouadjar B, Avril MF, Sarasin A, Daya-Grosjean L. Significantly high levels of ultraviolet-specific mutations in the smoothened gene in basal cell carcinomas from DNA repair-deficient xeroderma pigmentosum patients. *Cancer Res*. 2002; 62(24):7186–7189. [PubMed: 12499255]
- Dahmane N, Ruiz i Altaba A. Sonic hedgehog regulates the growth and patterning of the cerebellum. *Development*. 1999; 126(14):3089–3100. [PubMed: 10375501]
- Das S, Samant RS, Shevde LA. Nonclassical activation of Hedgehog signaling enhances multidrug resistance and makes cancer cells refractory to smoothened-targeting Hedgehog inhibition. *J Biol Chem*. 2013; 288(17):11824–11833. [PubMed: 23508962]

- Di Marcotullio L, Ferretti E, Greco A, et al. Numb is a suppressor of Hedgehog signalling and targets Gli1 for Itch-dependent ubiquitination. *Nat Cell Biol.* 2006; 8(12):1415–1423. [PubMed: 17115028]
- Dierker T, Dreier R, Petersen A, Bordych C, Grobe K. Heparan sulfate-modulated, metalloprotease-mediated sonic hedgehog release from producing cells. *J Biol Chem.* 2009; 284(12):8013–8022. [PubMed: 19176481]
- Dierks C, Beigi R, Guo GR, et al. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. *Cancer Cell.* 2008; 14(3):238–249. [PubMed: 18772113]
- Domingo-Domenech J, Vidal SJ, Rodriguez-Bravo V, et al. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. *Cancer Cell.* 2012; 22(3):373–388. [PubMed: 22975379]
- Douglas AE, Heim JA, Shen F, et al. The alpha subunit of the G protein G13 regulates activity of one or more Gli transcription factors independently of smoothened. *J Biol Chem.* 2011; 286(35):30714–30722. [PubMed: 21757753]
- Duarte JM, Biyani N, Baskaran K, Capitani G. An analysis of oligomerization interfaces in transmembrane proteins. *BMC Struct Biol.* 2013; 13:21. [PubMed: 24134166]
- Eberl M, Klingler S, Mangelberger D, et al. Hedgehog-EGFR cooperation response genes determine the oncogenic phenotype of basal cell carcinoma and tumour-initiating pancreatic cancer cells. *EMBO Mol Med.* 2012; 4(3):218–233. [PubMed: 22294553]
- Eggenchswiler JT, Espinoza E, Anderson KV. Rab23 is an essential negative regulator of the mouse Sonic hedgehog signalling pathway. *Nature.* 2001; 412(6843):194–198. [PubMed: 11449277]
- Endoh-Yamagami S, Evangelista M, Wilson D, et al. The mammalian Cos2 homolog Kif7 plays an essential role in modulating Hh signal transduction during development. *Curr Biol.* 2009; 19(15):1320–1326. [PubMed: 19592253]
- Epstein E Jr. Genetic determinants of basal cell carcinoma risk. *Med Pediatr Oncol.* 2001; 36(5):555–558. [PubMed: 11340611]
- Fan Q, He M, Sheng T, et al. Requirement of TGF{beta} Signaling for SMO-mediated Carcinogenesis. *J Biol Chem.* 2010; 285(47):36570–36576. [PubMed: 20858897]
- Fei DL, Sanchez-Mejias A, Wang Z, et al. Hedgehog signaling regulates bladder cancer growth and tumorigenicity. *Cancer Res.* 2012; 72(17):4449–4458. [PubMed: 22815529]
- Feldmann G, Dhara S, Fendrich V, et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. *Cancer Res.* 2007; 67(5):2187–2196. [PubMed: 17332349]
- Feldmann G, Fendrich V, McGovern K, et al. An orally bio-available small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. *Mol Cancer Ther.* 2008; 7(9):2725–2735. [PubMed: 18790753]
- Fernandez LA, Squatrito M, Northcott P, et al. Oncogenic YAP promotes radioresistance and genomic instability in medulloblastoma through IGF2-mediated Akt activation. *Oncogene.* 2012; 31(15):1923–1937. [PubMed: 21874045]
- Gao J, Graves S, Koch U, et al. Hedgehog signaling is dispensable for adult hematopoietic stem cell function. *Cell Stem Cell.* 2009; 4(6):548–558. [PubMed: 19497283]
- Garcia-Gonzalo FR, Corbit KC, Sirerol-Piquer MS, et al. A transition zone complex regulates mammalian ciliogenesis and ciliary membrane composition. *Nat Genet.* 2011; 43(8):776–784. [PubMed: 21725307]
- Goodrich LV, Milenkovic L, Higgins KM, Scott MP. Altered neural cell fates and medulloblastoma in mouse patched mutants. *Science.* 1997; 277(5329):1109–1113. [PubMed: 9262482]
- Gorlin RJ. Nevoid basal-cell carcinoma syndrome. *Medicine.* 1987; 66(2):98–113. [PubMed: 3547011]
- Gu D, Fan Q, Zhang X, Xie J. A role for transcription factor STAT3 signaling in oncogene smoothened-driven carcinogenesis. *J Biol Chem.* 2012; 287(45):38356–38366. [PubMed: 22992748]
- Gu D, Liu H, Su GH, et al. Combining hedgehog signaling inhibition with focal irradiation on reduction of pancreatic cancer metastasis. *Mol Cancer Ther.* 2013; 12(6):1038–1048. [PubMed: 23468532]

- Hahn H, Wicking C, Zaphiropoulos PG, et al. Mutations of the human homolog of *Drosophila* patched in the nevoid basal cell carcinoma syndrome. *Cell*. 1996; 85(6):841–851. [PubMed: 8681379]
- Hahn H, Wojnowski L, Zimmer AM, Hall J, Miller G, Zimmer A. Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome. *Nat Med*. 1998; 4(5):619–622. [PubMed: 9585239]
- Han L, Pan Y, Wang B. Small ubiquitin-like modifier (SUMO) modification inhibits GLI2 protein transcriptional activity in vitro and in vivo. *J Biol Chem*. 2012; 287(24):20483–20489. [PubMed: 22549777]
- Hatley ME, Tang W, Garcia MR, et al. A mouse model of rhabdomyosarcoma originating from the adipocyte lineage. *Cancer Cell*. 2012; 22(4):536–546. [PubMed: 23079662]
- Heller E, Hurchla MA, Xiang J, et al. Hedgehog signaling inhibition blocks growth of resistant tumors through effects on tumor microenvironment. *Cancer Res*. 2012; 72(4):897–907. [PubMed: 22186138]
- Hillman RT, Feng BY, Ni J, et al. Neuropilins are positive regulators of Hedgehog signal transduction. *Genes Dev*. 2011; 25(22):2333–2346. [PubMed: 22051878]
- Hofmann I, Stover EH, Cullen DE, et al. Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis. *Cell Stem Cell*. 2009; 4(6):559–567. [PubMed: 19497284]
- Hoover AN, Wynkoop A, Zeng H, Jia J, Niswander LA, Liu A. C2cd3 is required for cilia formation and Hedgehog signaling in mouse. *Development*. 2008; 135(24):4049–4058. [PubMed: 19004860]
- Hsieh A, Ellsworth R, Hsieh D. Hedgehog/GLI1 regulates IGF dependent malignant behaviors in glioma stem cells. *J Cell Physiol*. 2011; 226(4):1118–1127. [PubMed: 20857406]
- Hsu SH, Zhang X, Yu C, et al. Kif7 promotes hedgehog signaling in growth plate chondrocytes by restricting the inhibitory function of Sufu. *Development*. 2011; 138(17):3791–3801. [PubMed: 21795282]
- Hsu YC, Li L, Fuchs E. Transit-amplifying cells orchestrate stem cell activity and tissue regeneration. *Cell*. 2014; 157(4):935–949. [PubMed: 24813615]
- Huang S, Yang L, An Y, et al. Expression of hedgehog signaling molecules in lung cancer. *Acta Histochem*. 2010
- Huang S, Zhang Z, Zhang C, et al. Activation of Smurf E3 ligase promoted by smoothened regulates hedgehog signaling through targeting patched turnover. *PLoS Biol*. 2013; 11(11):e1001721.
- Huangfu D, Anderson KV. Cilia and Hedgehog responsiveness in the mouse. *Proc Natl Acad Sci USA*. 2005; 102(32):11325–11330. [PubMed: 16061793]
- Huangfu D, Liu A, Rakeman AS, Murcia NS, Niswander L, Anderson KV. Hedgehog signalling in the mouse requires intraflagellar transport proteins. *Nature*. 2003; 426(6962):83–87. [PubMed: 14603322]
- Hui CC, Angers S. Gli proteins in development and disease. *Annu Rev Cell Dev Biol*. 2011; 27:513–537. [PubMed: 21801010]
- Huntzicker EG, Estay IS, Zhen H, Lokteva LA, Jackson PK, Oro AE. Dual degradation signals control Gli protein stability and tumor formation. *Genes Dev*. 2006; 20(3):276–281. [PubMed: 16421275]
- Huppke P, Wegener E, Bohrer-Rabel H, et al. Tectonic gene mutations in patients with Joubert syndrome. *EJHG, Eur J Hum Genet*. 2014
- Ignatius MS, Chen E, Elpek NM, et al. In vivo imaging of tumor-propagating cells, regional tumor heterogeneity, and dynamic cell movements in embryonal rhabdomyosarcoma. *Cancer Cell*. 2012; 21(5):680–693. [PubMed: 22624717]
- Inaguma S, Kasai K, Ikeda H. GLI1 facilitates the migration and invasion of pancreatic cancer cells through MUC5AC-mediated attenuation of E-cadherin. *Oncogene*. 2010
- Ingham PW, McMahon AP. Hedgehog signaling in animal development: paradigms and principles. *Genes Dev*. 2001; 15(23):3059–3087. [PubMed: 11731473]
- Ingham PW, Placzek M. Orchestrating ontogenesis: variations on a theme by sonic hedgehog. *Nat Rev Genet*. 2006; 7(11):841–850. [PubMed: 17047684]

- Jagani Z, Mora-Blanco EL, Sansam CG, et al. Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway. *Nat Med.* 2010; 16(12):1429–1433. [PubMed: 21076395]
- Javelaud D, Pierrat MJ, Mauviel A. Crosstalk between TGF-beta and hedgehog signaling in cancer. *FEBS Lett.* 2012; 586(14):2016–2025. [PubMed: 22609357]
- Jiang J. Regulation of Hh/Gli signaling by dual ubiquitin pathways. *Cell Cycle.* 2006; 5(21):2457–2463. [PubMed: 17102630]
- Johnson RL, Riddle RD, Tabin CJ. Mechanisms of limb patterning. *Curr Opin Genet Dev.* 1994; 4(4): 535–542. [PubMed: 7950321]
- Johnson RL, Rothman AL, Xie J, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. *Science.* 1996; 272(5268):1668–1671. [PubMed: 8658145]
- Johnson RW, Nguyen MP, Padalecki SS, et al. TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling. *Cancer Res.* 2011; 71(3):822–831. [PubMed: 21189326]
- Joost S, Almada LL, Rohnalter V, et al. GLI1 inhibition promotes epithelial-to-mesenchymal transition in pancreatic cancer cells. *Cancer Res.* 2012; 72(1):88–99. [PubMed: 22086851]
- Kawakami T, Kawcak T, Li YJ, Zhang W, Hu Y, Chuang PT. Mouse dispatched mutants fail to distribute hedgehog proteins and are defective in hedgehog signaling. *Development.* 2002; 129(24):5753–5765. [PubMed: 12421714]
- Keysar SB, Le PN, Anderson RT, et al. Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer. *Cancer Res.* 2013; 73(11):3381–3392. [PubMed: 23576557]
- Khaliullina H, Panakova D, Eugster C, Riedel F, Carvalho M, Eaton S. Patched regulates smoothened trafficking using lipoprotein-derived lipids. *Development.* 2009; 136(24):4111–4121. [PubMed: 19906846]
- Kijima C, Miyashita T, Suzuki M, Oka H, Fujii K. Two cases of nevoid basal cell carcinoma syndrome associated with meningioma caused by a PTCH1 or SUFU germline mutation. *Fam Cancer.* 2012; 11(4):565–570. [PubMed: 22829011]
- Kinzler KW, Vogelstein B. The GLI gene encodes a nuclear protein which binds specific sequences in the human genome. *Mol Cell Biol.* 1990; 10(2):634–642. [PubMed: 2105456]
- Kinzler KW, Ruppert JM, Bigner SH, Vogelstein B. The GLI gene is a member of the Kruppel family of zinc finger proteins. *Nature.* 1988; 332(6162):371–374. [PubMed: 2832761]
- Kogerman P, Grimm T, Kogerman L, et al. Mammalian sup-pressor-of-fused modulates nuclear-cytoplasmic shuttling of Gli-1. *Nat Cell Biol.* 1999; 1(5):312–319. [PubMed: 10559945]
- Koziel L, Kunath M, Kelly OG, Vortkamp A. Extl-dependent heparan sulfate regulates the range of Ihh signaling during endochondral ossification. *Dev Cell.* 2004; 6(6):801–813. [PubMed: 15177029]
- Lam CW, Xie J, To KF, et al. A frequent activated smoothened mutation in sporadic basal cell carcinomas. *Oncogene.* 1999; 18(3):833–836. [PubMed: 9989836]
- Law KK, Makino S, Mo R, Zhang X, Puvion-Randall V, Hui CC. Antagonistic and cooperative actions of Kif7 and Sufr define graded intracellular Gli activities in Hedgehog signaling. *PLoS One.* 2012; 7(11):e50193. [PubMed: 23166838]
- Lee JJ, Ekker SC, von Kessler DP, Porter JA, Sun BI, Beachy PA. Autoproteolysis in hedgehog protein biogenesis. *Science.* 1994; 266(5190):1528–1537. [PubMed: 7985023]
- Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. *Cancer Res.* 2007a; 67(3):1030–1037. [PubMed: 17283135]
- Li X, Deng W, Lobo-Ruppert SM, Ruppert JM. Gli1 acts through Snail and E-cadherin to promote nuclear signaling by beta-catenin. *Oncogene.* 2007b; 26(31):4489–4498. [PubMed: 17297467]
- Li C, Chi S, Xie J. Hedgehog signaling in skin cancers. *Cell Signal.* 2011a
- Li F, Shi W, Capurro M, Filmus J. Glypican-5 stimulates rhabdomyosarcoma cell proliferation by activating Hedgehog signaling. *J Cell Biol.* 2011b; 192(4):691–704. [PubMed: 21339334]

- Li S, Chen Y, Shi Q, Yue T, Wang B, Jiang J. Hedgehog-regulated ubiquitination controls smoothened trafficking and cell surface expression in *Drosophila*. *PLoS Biol*. 2012a; 10(1):e1001239.
- Li ZJ, Nieuwenhuis E, Nien W, et al. Kif7 regulates Gli2 through Sufu-dependent and -independent functions during skin development and tumorigenesis. *Development*. 2012b; 139(22):4152–4161. [PubMed: 23034632]
- Li ZJ, Mack SC, Mak TH, Angers S, Taylor MD, Hui CC. Evasion of p53 and G/M checkpoints are characteristic of Hh-driven basal cell carcinoma. *Oncogene*. 2013
- Lin SH, George TJ, Ben-Josef E, et al. Opportunities and challenges in the era of molecularly targeted agents and radiation therapy. *J Natl Cancer Inst*. 2013; 105(10):686–693. [PubMed: 23503600]
- Lin C, Yao E, Wang K, et al. Regulation of Sufu activity by p66beta and Mycbp provides new insight into vertebrate Hedgehog signaling. *Genes Dev*. 2014; 28(22):2547–2563. [PubMed: 25403183]
- Liu S, Dontu G, Mantle ID, et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. *Cancer Res*. 2006; 66(12):6063–6071. [PubMed: 16778178]
- Long J, Li B, Rodriguez-Blanco J, et al. The BET bromodomain inhibitor I-BET151 acts downstream of Smoothened to abrogate the growth of Hedgehog driven cancers. *J Biol Chem*. 2014
- Lum L, Yao S, Mozer B, et al. Identification of Hedgehog pathway components by RNAi in *Drosophila* cultured cells. *Science*. 2003; 299(5615):2039–2045. [PubMed: 12663920]
- Ma Y, Erkner A, Gong R, et al. Hedgehog-mediated patterning of the mammalian embryo requires transporter-like function of dispatched. *Cell*. 2002; 111(1):63–75. [PubMed: 12372301]
- Mainwaring LA, Kenney AM. Divergent functions for eIF4E and S6 kinase by sonic hedgehog mitogenic signaling in the developing cerebellum. *Oncogene*. 2011; 30(15):1784–1797. [PubMed: 21339731]
- Mao J, Ligon KL, Rakhlin EY, et al. A novel somatic mouse model to survey tumorigenic potential applied to the Hedgehog pathway. *Cancer Res*. 2006; 66(20):10171–10178. [PubMed: 17047082]
- Martinelli DC, Fan CM. Gas1 extends the range of Hedgehog action by facilitating its signaling. *Genes Dev*. 2007; 21(10):1231–1243. [PubMed: 17504940]
- May SR, Ashique AM, Karlen M, et al. Loss of the retrograde motor for IFT disrupts localization of Smo to cilia and prevents the expression of both activator and repressor functions of Gli. *Dev Biol*. 2005; 287(2):378–389. [PubMed: 16229832]
- McMahon AP, Ingham PW, Tabin CJ. Developmental roles and clinical significance of hedgehog signaling. *Curr Top Dev Biol*. 2003; 53:1–114. [PubMed: 12509125]
- Merchant M, Evangelista M, Luoh SM, et al. Loss of the serine/threonine kinase fused results in postnatal growth defects and lethality due to progressive hydrocephalus. *Mol Cell Biol*. 2005; 25(16):7054–7068. [PubMed: 16055717]
- Merchant A, Joseph G, Wang Q, Brennan S, Matsui W. Gli1 regulates the proliferation and differentiation of HSCs and myeloid progenitors. *Blood*. 2010; 115(12):2391–2396. [PubMed: 20107231]
- Molnar C, Holguin H, Mayor F Jr, Ruiz-Gomez A, de Celis JF. The G protein-coupled receptor regulatory kinase GPRK2 participates in Hedgehog signaling in *Drosophila*. *Proc Natl Acad Sci USA*. 2007; 104(19):7963–7968. [PubMed: 17483466]
- Myers BR, Sever N, Chong YC, et al. Hedgehog pathway modulation by multiple lipid binding sites on the smoothened effector of signal response. *Dev Cell*. 2013; 26(4):346–357. [PubMed: 23954590]
- Nachtergaele S, Whalen DM, Mydock LK, et al. Structure and function of the smoothened extracellular domain in vertebrate hedgehog signaling. *eLife*. 2013; 2:e01340. [PubMed: 24171105]
- Nedelcu D, Liu J, Xu Y, Jao C, Salic A. Oxysterol binding to the extracellular domain of Smoothened in Hedgehog signaling. *Nat Chem Biol*. 2013; 9(9):557–564. [PubMed: 23831757]
- Nitzki F, Zibat A, Frommhold A, et al. Uncommitted precursor cells might contribute to increased incidence of embryonal rhabdomyosarcoma in heterozygous Patched1-mutant mice. *Oncogene*. 2011; 30(43):4428–4436. [PubMed: 21602886]

- Ogden SK, Fei DL, Schilling NS, Ahmed YF, Hwa J, Robbins DJ. G protein Galphai functions immediately downstream of Smoothened in Hedgehog signalling. *Nature*. 2008; 456(7224):967–970. [PubMed: 18987629]
- Okada A, Charron F, Morin S, et al. Boc is a receptor for sonic hedgehog in the guidance of commissural axons. *Nature*. 2006; 444(7117):369–373. [PubMed: 17086203]
- Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. *Science*. 2009; 324(5933):1457–1461. [PubMed: 19460966]
- Ozdemir BC, Pentcheva-Hoang T, Carstens JL, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immune suppression and accelerates pancreatic cancer with reduced survival. *Cancer Cell*. 2014; 25(6):719–734. [PubMed: 24856586]
- Palm W, Swierczynska MM, Kumari V, Ehrhart-Bornstein M, Bornstein SR, Eaton S. Secretion and signaling activities of lipoprotein-associated hedgehog and non-sterol-modified hedgehog in flies and mammals. *PLoS Biol*. 2013; 11(3):e1001505.
- Pan Y, Bai CB, Joyner AL, Wang B. Sonic hedgehog signaling regulates Gli2 transcriptional activity by suppressing its processing and degradation. *Mol Cell Biol*. 2006; 26(9):3365–3377. [PubMed: 16611981]
- Park KS, Martelotto LG, Peifer M, et al. A crucial requirement for Hedgehog signaling in small cell lung cancer. *Nat Med*. 2011; 17(11):1504–1508. [PubMed: 21983857]
- Parker DS, White MA, Ramos AI, Cohen BA, Barolo S. The cis-regulatory logic of Hedgehog gradient responses: key roles for gli binding affinity, competition, and cooperativity. *Science Signal*. 2011; 4(176):ra38.
- Parra LM, Zou Y. Sonic hedgehog induces response of commissural axons to semaphorin repulsion during midline crossing. *Nat Neurosci*. 2010; 13(1):29–35. [PubMed: 19946319]
- Pelczar P, Zibat A, van Dop WA, et al. Inactivation of Patched 1 in mice leads to development of gastrointestinal stromal-like tumors that express Pdgfralpha but not kit. *Gastroenterology*. 2013; 144(1):134–144. e6. [PubMed: 23041331]
- Philipp M, Fralish GB, Meloni AR, et al. Smoothened signaling in vertebrates is facilitated by a G protein-coupled receptor kinase. *Mol Biol Cell*. 2008; 19(12):5478–5489. [PubMed: 18815277]
- Porter JA, von Kessler DP, Ekker SC, et al. The product of hedgehog autoproteolytic cleavage active in local and long-range signalling. *Nature*. 1995; 374(6520):363–366. [PubMed: 7885476]
- Porter JA, Young KE, Beachy PA. Cholesterol modification of hedgehog signaling proteins in animal development. *Science*. 1996; 274(5285):255–259. [PubMed: 8824192]
- Pressey JG, Anderson JR, Crossman DK, Lynch JC, Barr FG. Hedgehog pathway activity in pediatric embryonal rhabdomyosarcoma and undifferentiated sarcoma: a report from the Children's Oncology Group. *Pediatr Blood Cancer*. 2011; 57(6):930–938. [PubMed: 21618411]
- Putoux A, Thomas S, Coene KL, et al. KIF7 mutations cause fetal hydrolethrus and acrocallosal syndromes. *Nat Genet*. 2011; 43(6):601–606. [PubMed: 21552264]
- Putoux A, Nampoothiri S, Laurent N, et al. Novel KIF7 mutations extend the phenotypic spectrum of acrocallosal syndrome. *J Med Genet*. 2012; 49(11):713–720. [PubMed: 23125460]
- Queiroz KC, Ruela-de-Sousa RR, Fuhler GM, et al. Hedgehog signaling maintains chemoresistance in myeloid leukemic cells. *Oncogene*. 2010; 29(48):6314–6322. [PubMed: 20802532]
- Ramaswamy B, Lu Y, Teng KY, et al. Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway. *Cancer Res*. 2012; 72(19):5048–5059. [PubMed: 22875023]
- Rana R, Carroll CE, Lee HJ, et al. Structural insights into the role of the smoothened cysteine-rich domain in Hedgehog signalling. *Nature communications*. 2013; 4:2965.
- Read TA, Fogarty MP, Markant SL, et al. Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. *Cancer Cell*. 2009; 15(2):135–147. [PubMed: 19185848]
- Reifenberger J, Wolter M, Weber RG, et al. Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. *Cancer Res*. 1998; 58(9):1798–1803. [PubMed: 9581815]

- Reifenberger J, Wolter M, Knobbe CB, et al. Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. *Br J Dermatol*. 2005; 152(1):43–51. [PubMed: 15656799]
- Reiter JF, Skarnes WC. Tectonic, a novel regulator of the Hedgehog pathway required for both activation and inhibition. *Genes Dev*. 2006; 20(1):22–27. [PubMed: 16357211]
- Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. *Nature*. 2001; 414(6859):105–111. [PubMed: 11689955]
- Rhim AD, Oberstein PE, Thomas DH, et al. Stromal elements act to restrain, rather than support pancreatic ductal adenocarcinoma. *Cancer Cell*. 2014; 25(6):735–747. [PubMed: 24856585]
- Ribes V, Briscoe J. Establishing and interpreting graded Sonic Hedgehog signaling during vertebrate neural tube patterning: the role of negative feedback. *Cold Spring Harb Perspect Biol*. 2009; 1(2):a002014. [PubMed: 20066087]
- Riobo NA, Saucy B, Dilizio C, Manning DR. Activation of heterotrimeric G proteins by Smoothened. *Proc Natl Acad Sci USA*. 2006; 103(33):12607–12612. [PubMed: 16885213]
- Rodriguez-Blanco J, Schilling NS, Tokhunts R, et al. The hedgehog processing pathway is required for NSCLC growth and survival. *Oncogene*. 2013; 32(18):2335–2345. [PubMed: 22733134]
- Romer JT, Kimura H, Magdaleno S, et al. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice. *Cancer Cell*. 2004; 6(3):229–240. [PubMed: 15380514]
- Ruppert JM, Kinzler KW, Wong AJ, et al. The GLI-Kruppel family of human genes. *Mol Cell Biol*. 1988; 8(8):3104–3113. [PubMed: 2850480]
- Sanchez-Hernandez D, Sierra J, Ortigao-Farias JR, Guerrero I. The WIF domain of the human and *Drosophila* Wif-1 secreted factors confers specificity for Wnt or Hedgehog. *Development*. 2012; 139(20):3849–3858. [PubMed: 22951645]
- Sasaki H, Hui C, Nakafuku M, Kondoh H. A binding site for Gli proteins is essential for HNF-3beta floor plate enhancer activity in transgenics and can respond to Shh in vitro. *Development*. 1997; 124(7):1313–1322. [PubMed: 9118802]
- Seppala M, Depew MJ, Martinelli DC, Fan CM, Sharpe PT, Cobourne MT. Gas1 is a modifier for holoprosencephaly and genetically interacts with sonic hedgehog. *J Clin Invest*. 2007; 117(6):1575–1584. [PubMed: 17525797]
- Shaheen R, Faqeih E, Seidahmed MZ, et al. A TCTN2 mutation defines a novel Meckel Gruber syndrome locus. *Hum Mutat*. 2011; 32(6):573–578. [PubMed: 21462283]
- Sheng T, Chi S, Zhang X, Xie J. Regulation of Gli1 localization by the cAMP/protein kinase A signaling axis through a site near the nuclear localization signal. *J Biol Chem*. 2006; 281(1):9–12. [PubMed: 16293631]
- Shi S, Deng YZ, Zhao JS, et al. RACK1 promotes non-small-cell lung cancer tumorigenicity through activating sonic hedgehog signaling pathway. *J Biol Chem*. 2012; 287(11):7845–7858. [PubMed: 22262830]
- Shin K, Lee J, Guo N, et al. Hedgehog/Wnt feedback supports regenerative proliferation of epithelial stem cells in bladder. *Nature*. 2011; 472(7341):110–114. [PubMed: 21389986]
- Shin K, Lim A, Zhao C, et al. Hedgehog signaling restrains bladder cancer progression by eliciting stromal production of urothelial differentiation factors. *Cancer Cell*. 2014; 26(4):521–533. [PubMed: 25314078]
- Siggins SL, Nguyen NY, McCormack MP, et al. The Hedgehog receptor Patched1 regulates myeloid and lymphoid progenitors by distinct cell-extrinsic mechanisms. *Blood*. 2009; 114(5):995–1004. [PubMed: 19483124]
- Sims-Mourtada J, Izzo JG, Apisarnthanarax S, et al. Hedgehog: an attribute to tumor regrowth after chemoradiotherapy and a target to improve radiation response. *Clin Cancer Res*. 2006; 12(21):6565–6572. [PubMed: 17085672]
- Singh RR, Kunkalla K, Qu C, et al. ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma. *Oncogene*. 2011; 30(49):4874–4886. [PubMed: 21625222]

- Snuderl M, Batista A, Kirkpatrick ND, et al. Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. *Cell*. 2013; 152(5):1065–1076. [PubMed: 23452854]
- Song Z, Yue W, Wei B, et al. Sonic hedgehog pathway is essential for maintenance of cancer stem-like cells in human gastric cancer. *PLoS One*. 2011; 6(3):e17687.
- Speksnijder L, Cohen-Overbeek TE, Knapen MF, et al. A de novo GLI3 mutation in a patient with acrocallosal syndrome. *American J Med Genet Part A*. 2013; 161A(6):1394–1400.
- Stecca B, Mas C, Clement V, et al. Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways. *Proc Natl Acad Sci USA*. 2007; 104(14):5895–5900. [PubMed: 17392427]
- Steg AD, Bevis KS, Katre AA, et al. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. *Clin Cancer Res*. 2012a; 18(3):869–881. [PubMed: 22142828]
- Steg AD, Katre AA, Bevis KS, et al. Smoothed antagonists reverse taxane resistance in ovarian cancer. *Mol Cancer Ther*. 2012b; 11(7):1587–1597. [PubMed: 22553355]
- Stone DM, Hynes M, Armanini M, et al. The tumour-suppressor gene patched encodes a candidate receptor for Sonic hedgehog. *Nature*. 1996; 384(6605):129–134. [PubMed: 8906787]
- Su W, Meng F, Huang L, Zheng M, Liu W, Sun H. Sonic hedgehog maintains survival and growth of chronic myeloid leukemia progenitor cells through beta-catenin signaling. *Exp Hematol*. 2012; 40(5):418–427. [PubMed: 22240607]
- Suzuki T. How is digit identity determined during limb development? *Dev Growth Differ*. 2013; 55(1): 130–138. [PubMed: 23230964]
- Taipale J, Beachy PA. The Hedgehog and Wnt signalling pathways in cancer. *Nature*. 2001; 411(6835):349–354. [PubMed: 11357142]
- Taipale J, Cooper MK, Maiti T, Beachy PA. Patched acts catalytically to suppress the activity of Smoothed. *Nature*. 2002; 418(6900):892–897. [PubMed: 12192414]
- Takahashi T, Kawakami K, Mishima S, et al. Cyclopamine induces eosinophilic differentiation and upregulates CD44 expression in myeloid leukemia cells. *Leuk Res*. 2011; 35(5):638–645. [PubMed: 20971508]
- Takebe N, Harris PJ, Warren RQ, Ivy SP. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. *Nat Rev Clin Oncol*. 2011; 8(2):97–106. [PubMed: 21151206]
- Tanaka H, Nakamura M, Kameda C, et al. The Hedgehog signaling pathway plays an essential role in maintaining the CD44+CD24—/low subpopulation and the side population of breast cancer cells. *Anticancer Res*. 2009; 29(6):2147–2157. [PubMed: 19528475]
- Tang SN, Fu J, Nall D, Rodova M, Shankar S, Srivastava RK. Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics. *Int J Cancer*. 2012; 131(1):30–40. [PubMed: 21796625]
- Tang Y, Gholamin S, Schubert S, et al. Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. *Nat Med*. 2014; 20(7):732–740. [PubMed: 24973920]
- Tenzen T, Allen BL, Cole F, Kang JS, Krauss RS, McMahon AP. The cell surface membrane proteins Cdo and Boc are components and targets of the Hedgehog signaling pathway and feedback network in mice. *Dev Cell*. 2006; 10(5):647–656. [PubMed: 16647304]
- Tian H, Callahan CA, DuPree KJ, et al. Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. *Proc Natl Acad Sci USA*. 2009; 106(11):4254–4259. [PubMed: 19246386]
- Tostar U, Malm CJ, Meis-Kindblom JM, Kindblom LG, Toftgard R, Uden AB. Deregulation of the hedgehog signalling pathway: a possible role for the PTCH and SUFU genes in human rhabdomyoma and rhabdomyosarcoma development. *J Pathol*. 2006; 208(1):17–25. [PubMed: 16294371]
- Toyoda H, Kinoshita-Toyoda A, Fox B, Selleck SB. Structural analysis of glycosaminoglycans in animals bearing mutations in sugarless, sulfateless, and tout-velu. *Drosophila* homologues of vertebrate genes encoding glycosaminoglycan biosynthetic enzymes. *J Biol Chem*. 2000; 275(29):21856–21861. [PubMed: 10806213]

- Visbal AP, LaMarca HL, Villanueva H, et al. Altered differentiation and paracrine stimulation of mammary epithelial cell proliferation by conditionally activated smoothened. *Dev Biol.* 2011; 352(1):116–127. [PubMed: 21276786]
- Wallace VA. Purkinje-cell-derived sonic hedgehog regulates granule neuron precursor cell proliferation in the developing mouse cerebellum. *Curr Biol.* 1999; 9(8):445–448. [PubMed: 10226030]
- Walsh DM, Shalev SA, Simpson MA, et al. Acrocallosal syndrome: identification of a novel KIF7 mutation and evidence for oligogenic inheritance. *Eur J Med Genet.* 2013; 56(1):39–42. [PubMed: 23142271]
- Wang B, Li Y. Evidence for the direct involvement of β TrCP in Gli3 protein processing. *Proc Natl Acad Sci USA.* 2006; 103(1):33–38. [PubMed: 16371461]
- Wang C, Pan Y, Wang B. Suppressor of fused and Spop regulate the stability, processing and function of Gli2 and Gli3 full-length activators but not their repressors. *Development.* 2010a; 137(12):2001–2009. [PubMed: 20463034]
- Wang DH, Clemons NJ, Miyashita T, et al. Aberrant epithelial-mesenchymal Hedgehog signaling characterizes Barrett's metaplasia. *Gastroenterology.* 2010b; 138(5):1810–1822. [PubMed: 20138038]
- Wang Y, Davidow L, Arvanites AC, et al. Glucocorticoid compounds modify smoothened localization and hedgehog pathway activity. *Chem Biol.* 2012a; 19(8):972–982. [PubMed: 22921064]
- Wang Y, Ding Q, Yen CJ, et al. The crosstalk of mTOR/ S6K1 and Hedgehog pathways. *Cancer Cell.* 2012b; 21(3):374–387. [PubMed: 22439934]
- Wang C, Wu H, Katritch V, et al. Structure of the human smoothened receptor bound to an antitumour agent. *Nature.* 2013; 497(7449):338–343. [PubMed: 23636324]
- Wechsler-Reya RJ, Scott MP. Control of neuronal precursor proliferation in the cerebellum by Sonic Hedgehog. *Neuron.* 1999; 22(1):103–114. [PubMed: 10027293]
- Weierstall U, James D, Wang C, et al. Lipidic cubic phase injector facilitates membrane protein serial femtosecond crystallography. *Nat Commun.* 2014; 5:3309. [PubMed: 24525480]
- Wilson CW, Nguyen CT, Chen MH, et al. Fused has evolved divergent roles in vertebrate Hedgehog signalling and motile ciliogenesis. *Nature.* 2009; 459(7243):98–102. [PubMed: 19305393]
- Witt RM, Hecht ML, Pazyra-Murphy MF, et al. Heparan sulfate proteoglycans containing a glypican 5 core and 2-O-sulfo-iduronic acid function as sonic hedgehog co-receptors to promote proliferation. *J Biol Chem.* 2013
- Xia R, Jia H, Fan J, Jiu Y, Jia J. USP8 promotes smoothened signaling by preventing its ubiquitination and changing its subcellular localization. *PLoS Biol.* 2012; 10(1):e1001238.
- Xie J, Murone M, Luoh SM, et al. Activating smoothened mutations in sporadic basal-cell carcinoma. *Nature.* 1998; 391(6662):90–92. [PubMed: 9422511]
- Xie J, Aszterbaum M, Zhang X, et al. A role of PDGFR α in basal cell carcinoma proliferation. *Proc Natl Acad Sci USA.* 2001; 98(16):9255–9259. [PubMed: 11481486]
- Yang L, Xie G, Fan Q, Xie J. Activation of the hedgehog-signaling pathway in human cancer and the clinical implications. *Oncogene.* 2010; 29(4):469–481. [PubMed: 19935712]
- Yang L, Wang LS, Chen XL, et al. Hedgehog signaling activation in the development of squamous cell carcinoma and adenocarcinoma of esophagus. *Int J Biochem Mol Biol.* 2012; 3(1):46–57. [PubMed: 22509480]
- Yao S, Lum L, Beachy P. The ihog cell-surface proteins bind Hedgehog and mediate pathway activation. *Cell.* 2006; 125(2):343–357. [PubMed: 16630821]
- Yavari A, Nagaraj R, Owusu-Ansah E, et al. Role of lipid metabolism in smoothened derepression in hedgehog signaling. *Dev Cell.* 2010; 19(1):54–65. [PubMed: 20643350]
- Yoshikawa R, Nakano Y, Tao L, et al. Hedgehog signal activation in oesophageal cancer patients undergoing neoadjuvant chemoradiotherapy. *Br J Cancer.* 2008; 98(10):1670–1674. [PubMed: 18475300]
- Yue S, Tang LY, Tang Y, et al. Requirement of Smurf-mediated endocytosis of Patched 1 in sonic hedgehog signal reception. *eLife* 3. 2014

- Zahreddine HA, Culjkovic-Kraljacic B, Assouline S, et al. The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation. *Nature*. 2014; 511(7507):90–93. [PubMed: 24870236]
- Zhang Q, Davenport JR, Croyle MJ, Haycraft CJ, Yoder BK. Disruption of IFT results in both exocrine and endocrine abnormalities in the pancreas of Tg737(orpk) mutant mice. *Lab Invest*. 2005; 85(1):45–64. [PubMed: 15580285]
- Zhang W, Kang JS, Cole F, Yi MJ, Krauss RS. Cdo functions at multiple points in the Sonic Hedgehog pathway, and Cdo-deficient mice accurately model human holoprosencephaly. *Dev Cell*. 2006; 10(5):657–665. [PubMed: 16647303]
- Zhang Q, Shi Q, Chen Y, et al. Multiple Ser/Thr-rich degrons mediate the degradation of Ci/Gli by the Cul3-HIB/SPOP E3 ubiquitin ligase. *Proc Natl Acad Sci USA*. 2009; 106(50):21191–21196. [PubMed: 19955409]
- Zhao Y, Tong C, Jiang J. Hedgehog regulates smoothened activity by inducing a conformational switch. *Nature*. 2007; 450(7167):252–258. [PubMed: 17960137]
- Zhao C, Chen A, Jamieson CH, et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. *Nature*. 2009; 458(7239):776–779. [PubMed: 19169242]

Fig. 1.

A diagram of Hh signaling in mammalian cells. SMO is the key signal transducer of the Hh pathway. In the absence of the Hh ligands, Hh receptor PTC is localized in the cilium to inhibit SMO signaling. Co-receptors of Hh include CDO (cell adhesion molecule-related/down-regulated by oncogenes), Brother of CDO (BOC), Gas1, Glypican 3 (GPC3) and GPC5. Wnt inhibitory factor-1 (WIF1) can also regulate Hh signaling through association with CDO, BOC or GPC5. Gli molecules are processed with help of Su (Fu)/KIF7, β -TRCP molecules into repressor forms, which turn off the Hh signaling pathway. Other negative regulators of Gli molecules include Rab23, Protein kinase A (PKA), Suppressor of Fused (SuFu), tumor suppressor SNF5, Culin 3 (Cul3), p66 β and Itchy E3 ubiquitin ligase (Itch) through regulation Gli protein modifications, nuclear-cytoplasm shuttling as well as transcriptional activities. In the presence of Hh, PTC is shuttled out of cilium and is unable to inhibit SMO. The ciliary localization of SMO is thought to require β -arrestin 2 (β Arr2) and G protein coupled receptor kinase 2 (GRK2). Hh reception promotes SMO conformational changes to form dimers/oligomers. Gli molecules are then processed to active forms (GliA), which will activate the Hh target genes. KIF and SuFu can inhibit this

process. Myc^{bp} and protein kinase C isoform τ/λ (PK τ/λ) positively regulate Gli transcriptional activity. Positive regulators are in *red*, negative regulators are in *blue* and target genes are in *pink*. KIF7 can function (in *black*) as a negative regulator or a positive regulator. The interacting pathways with the Hh pathway are in *green*. Although the role of cilium for Hh signaling during embryonic development is well established, cancer cells generally lack cilia. It has been demonstrated that lack of cilia prevents development of BCCs in mice, it is not clear whether this is true for all other types of Hh signaling-associated cancer (color figure online)

Fig. 2.

Different roles of Hh signaling in cancer. Hh signaling in cancer may function in three manners: (1) a tumor driver; (2) a tumor promoter; and (3) a treatment resistant factor. In mice, activation of Hh signaling, via mutations of PTCH1 or SMO, drives development of basal cell carcinomas, medulloblastoma, rhabdomyosarcomas and GISTs, indicating that Hh signaling is the tumor drive for these four types of cancer. In the humans, gene mutations occur frequently in these tumor types. For small cell lung cancer, activation of Hh signaling is not sufficient to drive tumor formation. However, expression of mutant SMO, SmoM2, accelerates development of SCLC derived from Rbl/p53 deletion and Smo deletion reduces the tumor development. Thus, Hh signaling is a tumor promoter for SCLC. In addition, Hh signaling is activated in chemoresistant cancer cells in prostate and ovarian cancer, and inhibition of Hh signaling can sensitize cancer cells to chemotherapy